치매 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 적응증별, 약제 클래스별, 지역별＆경쟁(2021-2031년)

The global dementia drugs market is projected to expand significantly, from USD 15.17 billion in 2025 to USD 21.42 billion by 2031, achieving a compound annual growth rate (CAGR) of 5.92%. This market includes various pharmaceutical agents like cholinesterase inhibitors, NMDA receptor antagonists, and innovative disease-modifying immunotherapies, all aimed at reducing cognitive decline and targeting the root causes of neurodegenerative conditions. The main factor fueling this growth is the increasing global elderly population, which inherently leads to a higher prevalence of Alzheimer's disease and other dementias. This expanding patient demographic urgently requires therapeutic interventions, prompting considerable investment in drug discovery. For instance, in 2025, about 7.2 million Americans aged 65 and older are estimated to be living with Alzheimer's dementia, highlighting a critical and rising need for effective medical treatments.

However, despite this strong demand, the market is constrained by a high failure rate in clinical trials. The intricate biological nature of neurodegenerative diseases often leads to expensive late-stage development failures, deterring investment and complicating regulatory approvals. This ongoing challenge in proving the clinical effectiveness of new compounds poses a financial and operational obstacle, impeding the launch of new therapies and limiting the overall growth of the global industry.

Market Driver

The primary force driving the dementia drugs market is the increasing global prevalence of Alzheimer's disease and related dementias. With rising global life expectancy, the elderly population-more susceptible to neurodegenerative conditions-is growing, creating a vast patient base needing continuous pharmaceutical care. This demographic trend places substantial economic pressure on healthcare systems, making effective treatments to reduce care costs a top priority. For instance, in 2024, the cost of caring for individuals with Alzheimer's and other dementias in the United States was estimated at $360 billion, highlighting the significant financial motivation for therapeutic interventions. Concurrently, the introduction of innovative disease-modifying therapies is transforming the industry by targeting underlying pathologies rather than just symptoms. Recent regulatory approvals for anti-amyloid agents signify a pivotal shift, confirming the scientific viability of reducing brain plaque to slow disease progression. For example, Eli Lilly's Kisunla(TM) (donanemab-azbt), recently approved by the FDA, demonstrated a reduction in cognitive and functional decline by up to 35% in Phase 3 trials. Such efficacy is quickly leading to commercial adoption, with manufacturing expanding to meet patient needs, as evidenced by Biogen's Leqembi achieving approximately $67 million in global in-market sales in Q3 2024, indicating strong initial demand for this new class of drugs.

Market Challenge

A primary impediment to the global dementia drugs market is the high attrition rate in clinical trials. This difficulty arises from the complex pathophysiology of neurodegenerative diseases, which often causes drug candidates to fail in late-stage development following extensive and expensive research. These failures impose considerable financial strain on pharmaceutical companies, depleting capital and creating an investment environment averse to risk, thereby delaying new drug discovery initiatives. Consequently, the industry encounters a bottleneck where successful commercialization of innovative therapies is infrequent relative to the substantial investments made, directly hindering revenue growth and market expansion. This ongoing struggle to introduce effective treatments exacerbates the economic imperative that the industry is striving to address. The total national cost of caring for individuals with Alzheimer's and other dementias is projected to reach $384 billion in 2025, highlighting the vast market potential that remains untapped because the industry cannot surmount clinical obstacles and provide approved, disease-modifying agents to a waiting patient population.

Market Trends

The diversification of R&D pipelines to include tau protein and neuroinflammation targets is significantly reshaping the sector's direction. This approach addresses the intricate, multifactorial pathology of neurodegenerative diseases beyond just amyloid-beta accumulation. Pharmaceutical developers are increasingly exploring mechanisms such as tau aggregation, synaptic plasticity, and neuroinflammation to overcome the limitations of single-target therapies and enhance clinical results for a wider patient demographic. This strategic pivot is evident in the growing number of clinical activities focusing on these new biological targets; as of early 2025, there were 182 active clinical trials evaluating 138 unique drug candidates, marking a notable increase in non-amyloid investigative agents. Concurrently, the integration of blood-based biomarkers for patient stratification and monitoring is boosting market growth by offering accessible screening tools that replace invasive and expensive diagnostic procedures like PET scans and lumbar punctures. These diagnostic innovations facilitate earlier disease detection and more accurate patient selection for clinical trials, thereby streamlining drug development and enabling prompt administration of disease-modifying treatments. The commercial potential of this trend is underscored by the high diagnostic accuracy of new assays, with some blood-based tests demonstrating over 90% accuracy compared to traditional methods, confirming their value in standard clinical practice.

Key Market Players

• AstraZeneca PLC
• Aurobindo Pharma Limited
• Eli Lilly & Co
• Johnson & Johnson
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
• Zydus Lifesciences Ltd
• Biogen Inc
• GSK PLC
• Merck & Co Inc

Report Scope

In this report, the Global Dementia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia Drugs Market, By Indications

• Alzheimer's Disease
• Lewy Body Dementia
• Parkinsons Disease Dementia
• Vascular Dementia

Dementia Drugs Market, By Drug Class

• Cholinesterase Inhibitors
• Glutamate Inhibitors
• MAO Inhibitors

Dementia Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia Drugs Market.

Available Customizations:

Global Dementia Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dementia Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
  • 5.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Dementia Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indications
  • 6.2.2. By Drug Class
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dementia Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indications
      • 6.3.1.2.2. By Drug Class
  • 6.3.2. Canada Dementia Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indications
      • 6.3.2.2.2. By Drug Class
  • 6.3.3. Mexico Dementia Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indications
      • 6.3.3.2.2. By Drug Class

7. Europe Dementia Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indications
  • 7.2.2. By Drug Class
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dementia Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indications
      • 7.3.1.2.2. By Drug Class
  • 7.3.2. France Dementia Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indications
      • 7.3.2.2.2. By Drug Class
  • 7.3.3. United Kingdom Dementia Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indications
      • 7.3.3.2.2. By Drug Class
  • 7.3.4. Italy Dementia Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indications
      • 7.3.4.2.2. By Drug Class
  • 7.3.5. Spain Dementia Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indications
      • 7.3.5.2.2. By Drug Class

8. Asia Pacific Dementia Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indications
  • 8.2.2. By Drug Class
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dementia Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indications
      • 8.3.1.2.2. By Drug Class
  • 8.3.2. India Dementia Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indications
      • 8.3.2.2.2. By Drug Class
  • 8.3.3. Japan Dementia Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indications
      • 8.3.3.2.2. By Drug Class
  • 8.3.4. South Korea Dementia Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indications
      • 8.3.4.2.2. By Drug Class
  • 8.3.5. Australia Dementia Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indications
      • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Dementia Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indications
  • 9.2.2. By Drug Class
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dementia Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indications
      • 9.3.1.2.2. By Drug Class
  • 9.3.2. UAE Dementia Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indications
      • 9.3.2.2.2. By Drug Class
  • 9.3.3. South Africa Dementia Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indications
      • 9.3.3.2.2. By Drug Class

10. South America Dementia Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indications
  • 10.2.2. By Drug Class
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dementia Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indications
      • 10.3.1.2.2. By Drug Class
  • 10.3.2. Colombia Dementia Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indications
      • 10.3.2.2.2. By Drug Class
  • 10.3.3. Argentina Dementia Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indications
      • 10.3.3.2.2. By Drug Class

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dementia Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Aurobindo Pharma Limited
• 15.3. Eli Lilly & Co
• 15.4. Johnson & Johnson
• 15.5. Pfizer Inc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Zydus Lifesciences Ltd
• 15.8. Biogen Inc
• 15.9. GSK PLC
• 15.10. Merck & Co Inc

16. Strategic Recommendations

17. About Us & Disclaimer